Oncology · ICMR

Breast cancer

ICMR

Source:ICMR Consensus Document for Management of Carcinoma of the Breast (2022)NCCN Breast Cancer Guidelines (2022)St Gallen Consensus (2022)

Verified Apr 2026

Ask House about this guideline

Red Flags

New breast lump, skin tethering, peau d'orange, nipple retraction or discharge, axillary lymphadenopathy — same-day imaging and triple assessment^[1]
Inflammatory breast cancer (rapid skin changes, oedema, erythema, peau d'orange) — emergent multidisciplinary oncology; neoadjuvant chemotherapy^[1]
BRCA1/2 or other high-penetrance mutation in patient or strong family history — clinical genetics; consider risk-reducing surgery and intensified surveillance^[1]
Pregnancy with newly diagnosed breast cancer — multidisciplinary oncology + obstetric; staging-appropriate chemotherapy from second trimester possible^[1]

First-line treatment

Interventions

Multidisciplinary tumour board for all^[1]
Surgical, medical, and radiation oncology + radiology + pathology; treatment driven by stage and molecular subtype (luminal A/B, HER2-positive, triple-negative)
Surgery — BCS or mastectomy^[1]
Breast-conserving surgery with whole-breast radiotherapy is equivalent to mastectomy for early-stage in survival; mastectomy for large tumour:breast ratio, multicentric disease, or contraindication to RT; sentinel lymph node biopsy for clinically node-negative
Adjuvant radiotherapy^[1]
Whole-breast RT after BCS; post-mastectomy RT for ≥4 positive nodes, T3+, or close margins; nodal RT per axillary status
Genomic risk-stratification (Oncotype DX, MammaPrint)^[1]
ER-positive HER2-negative N0 disease — informs decision on adjuvant chemotherapy where benefit uncertain; access varies by setting

First-line drug therapy

Drug	Class	Adult	Paediatric	Notes
Tamoxifen^[1]	Selective estrogen receptor modulator	20 mg PO daily × 5–10 years	—	Adjuvant for premenopausal ER-positive; risk of VTE and endometrial cancer — counsel about postmenopausal bleeding; CYP2D6 interactions (avoid SSRIs that inhibit CYP2D6 like paroxetine, fluoxetine)
Aromatase inhibitor (anastrozole, letrozole, exemestane)^[1]	Aromatase inhibitor	Anastrozole 1 mg PO daily; letrozole 2.5 mg PO daily; exemestane 25 mg PO daily — × 5–10 years	—	Adjuvant for postmenopausal ER-positive; switch from tamoxifen at menopause; bone loss — DXA and calcium/vitamin D ± bisphosphonate; arthralgia
Trastuzumab^[1]	Anti-HER2 monoclonal antibody	Loading 8 mg/kg IV then 6 mg/kg every 3 weeks × 1 year; or weekly schedule	—	All HER2-positive (IHC 3+ or FISH amplified); cardiotoxicity — baseline and serial echocardiogram; combine with chemotherapy then continue alone
Pertuzumab + trastuzumab + chemotherapy^[1]	Dual HER2 blockade	Pertuzumab 840 mg loading then 420 mg IV every 3 weeks	—	Neoadjuvant or adjuvant in HER2-positive; combine with trastuzumab and taxane; cardiac monitoring
CDK4/6 inhibitor (palbociclib, ribociclib, abemaciclib)^[1]	Cyclin-dependent kinase inhibitor	Palbociclib 125 mg PO daily 21/28; ribociclib 600 mg PO daily 21/28; abemaciclib 150 mg PO BD continuous	—	Combined with endocrine therapy in advanced ER-positive HER2-negative disease and selected high-risk early-stage; neutropenia, diarrhoea (abemaciclib), QTc (ribociclib)
Neoadjuvant/adjuvant taxane + anthracycline chemotherapy^[1]	Combination chemotherapy	AC-T or TC regimens per local protocol; dose-dense or weekly paclitaxel options	—	Standard for triple-negative, high-risk ER-positive, HER2-positive (with trastuzumab); cardiotoxicity, neuropathy, alopecia, neutropenia
PARP inhibitor (olaparib, talazoparib)^[1]	Poly ADP-ribose polymerase inhibitor	Olaparib 300 mg PO BD; talazoparib 1 mg PO daily	—	BRCA-mutated metastatic and selected adjuvant high-risk early-stage; counselling for genetic testing; haematological monitoring

Tamoxifen^[1]

Selective estrogen receptor modulator

Adult: 20 mg PO daily × 5–10 years
Paediatric: —

Adjuvant for premenopausal ER-positive; risk of VTE and endometrial cancer — counsel about postmenopausal bleeding; CYP2D6 interactions (avoid SSRIs that inhibit CYP2D6 like paroxetine, fluoxetine)

Aromatase inhibitor (anastrozole, letrozole, exemestane)^[1]

Aromatase inhibitor

Adult: Anastrozole 1 mg PO daily; letrozole 2.5 mg PO daily; exemestane 25 mg PO daily — × 5–10 years
Paediatric: —

Adjuvant for postmenopausal ER-positive; switch from tamoxifen at menopause; bone loss — DXA and calcium/vitamin D ± bisphosphonate; arthralgia

Trastuzumab^[1]

Anti-HER2 monoclonal antibody

Adult: Loading 8 mg/kg IV then 6 mg/kg every 3 weeks × 1 year; or weekly schedule
Paediatric: —

All HER2-positive (IHC 3+ or FISH amplified); cardiotoxicity — baseline and serial echocardiogram; combine with chemotherapy then continue alone

Pertuzumab + trastuzumab + chemotherapy^[1]

Dual HER2 blockade

Adult: Pertuzumab 840 mg loading then 420 mg IV every 3 weeks
Paediatric: —

Neoadjuvant or adjuvant in HER2-positive; combine with trastuzumab and taxane; cardiac monitoring

CDK4/6 inhibitor (palbociclib, ribociclib, abemaciclib)^[1]

Cyclin-dependent kinase inhibitor

Adult: Palbociclib 125 mg PO daily 21/28; ribociclib 600 mg PO daily 21/28; abemaciclib 150 mg PO BD continuous
Paediatric: —

Combined with endocrine therapy in advanced ER-positive HER2-negative disease and selected high-risk early-stage; neutropenia, diarrhoea (abemaciclib), QTc (ribociclib)

Neoadjuvant/adjuvant taxane + anthracycline chemotherapy^[1]

Combination chemotherapy

Adult: AC-T or TC regimens per local protocol; dose-dense or weekly paclitaxel options
Paediatric: —

Standard for triple-negative, high-risk ER-positive, HER2-positive (with trastuzumab); cardiotoxicity, neuropathy, alopecia, neutropenia

PARP inhibitor (olaparib, talazoparib)^[1]

Poly ADP-ribose polymerase inhibitor

Adult: Olaparib 300 mg PO BD; talazoparib 1 mg PO daily
Paediatric: —

BRCA-mutated metastatic and selected adjuvant high-risk early-stage; counselling for genetic testing; haematological monitoring

Safety-net

Be breast-aware: know what is normal for you and report any new lump, nipple change, skin change, or unexplained pain^[1]
Attend recommended mammography appointments — most early breast cancers are detected on screening before symptoms appear^[1]
Adjuvant therapy can last 5–10 years — adherence is the single biggest determinant of long-term survival; speak to your oncology team about side effects rather than stopping^[1]

Referral criteria

Suspicious clinical lesion, abnormal mammogram, or biopsy-proven cancerBreast cancer multidisciplinary clinic^[1]
Inflammatory breast cancer or rapidly progressive diseaseTertiary breast oncology same-week^[1]
BRCA1/2 mutation or strong family historyClinical genetics; consider risk-reducing mastectomy and salpingo-oophorectomy^[1]
Pregnancy with newly diagnosed breast cancerJoint oncology and obstetric clinic; staging-appropriate management^[1]

Clinical summary

Risk-stratified screening, triple-assessment diagnosis, and stage- and subtype-driven treatment of breast cancer in adult women.

References

1.ICMR Consensus Document for Management of Carcinoma of the Breast (2022); NCCN Breast Cancer Guidelines; St Gallen Consensus (2022)

Drug

Class

Adult

Paediatric

Notes